An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
The treatment period is planned to run until the market approval of seralutinib or until the study is terminated.
Inclusion Criteria:
Exclusion Criteria:
ClinicalTrials@gossamerbio.com1-866-668-4083
Los Angeles, California 90073, United States
Atlanta, Georgia 30309, United States
Albuquerque, New Mexico 87131, United States
Oklahoma City, Oklahoma 73112, United States
Philadelphia, Pennsylvania 19104, United States
Philadelphia, Pennsylvania 19140, United States
Charleston, South Carolina 29425, United States
Houston, Texas 77030, United States
San Antonio, Texas 78229, United States
Belo Horizonte, Brazil
Blumenau, Brazil
Porto Alegre, Brazil
São Paulo, Brazil
São Paulo, Brazil
Prague, Czechia
Prague, Czechia
Lille, France
Cologne, Germany
Dresden, Germany
Giessen, Germany
Heidelberg, Germany
Würzburg, Germany
Athens, Greece
Thessaloniki, Greece
Bologna, Italy
Shinjuku-Ku, Japan
Krakow, Poland
Otwock, Poland
Bucharest, Romania
Cluj-Napoca, Romania